By Bill Carey
SA国际传媒
NEW YORK 鈥� , a biotechnology company focused on hemostatic medical device technologies, received U.S. Food and Drug Administration clearance for for the temporary external use for controlling moderate to severe bleeding.
Cresilon鈥檚 plant-based hemostatic gel technology is designed to stop and control life-threatening bleeding, according to a .
鈥淭he ability to rapidly stop bleeding at the point of care and halt a life-threatening hemorrhage can be the difference between life and death for people with traumatic wounds,鈥� Cresilon CEO and co-founder Joe Landolina said. 鈥淭he FDA clearance for TRAUMAGEL is a monumental milestone for Cresilon and brings us another step forward in our mission to save lives and transform the standard of care in wound treatment.鈥�
TRAUMAGEL is Cresilon鈥檚 second FDA clearance for human use. The first was granted in 2023 for Cresilon Hemostatic Gel for minor cuts, lacerations and abrasions.
